Capital Flow Monitor · Sponsors · CIK 1746139
Auron Therapeutics, Inc.
1 Grove Street, Wellesley, MA, 02482-9998 · 310-922-5881
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$42.3M
Sold
$27.3M
% sold
64.5%
Investors
16
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | D | 506(b) | $12.0M | $7.1M | 59.3% | 14 | EDGAR ↗ |
| 2025-12-23 | D/A ·current | 506(b) | $42.3M | $27.3M | 64.5% | 16 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Katharine Yen — Executive Officer / Director, Newton, MA
-
Alexandra Cantley — Director, Newton, MA
3 other raises
- Polaris Partners XI, L.P. $0 of $500.0M · 0.0%
- Crossbow Therapeutics, Inc. $30.3M of $80.0M · 37.8%
- Cirrus Therapeutics, Inc. $6.7M of $15.7M · 42.7%
- Briggs Duncan Morrison — Director, Newton, MA
-
Anna French — Director, Newton, MA
2 other raises
- Entact Bio, Inc. $10.0M of $10.0M · 100.0%
- Renasant Bio, Inc. $30.0M of $30.0M · 100.0%
-
Pini Orbach — Director, Newton, MA
1 other raise
- Entact Bio, Inc. $10.0M of $10.0M · 100.0%
-
Serge Messerlian — Director, Newton, MA
1 other raise
- Plexium, Inc. $60.1M of $60.1M · 100.0%
-
Victoria Richon — Director, Newton, MA
1 other raise
- Entact Bio, Inc. $10.0M of $10.0M · 100.0%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.